> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Fast Track Status for Axsome Depression Drug Combo
- URL: https://www.fdaweb.com/fast-track-status-for-axsome-depression-drug-combo/
- Published: 2017-02-16T12:00:00.000Z
- Updated: 2026-09-14T22:07:14.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5137996

FDA has granted Axsome Therapeutics fast track status for AXS-05 (bupropion and dextromethorphan in combination) for treating treatment-resistant depression. The therapy is currently being evaluated in the STRIDE-1 study, a Phase 3, randomized, double-blind, active-controlled trial. AXS-05 uses Axsome’s technology of combining the two drugs. The company says dextromethorphan is an NMDA receptor antagonist, sigma-1 receptor agonist, and inhibitor of the serotonin and norepinephrine transporter. Bupropion works to increase the bioavailability of dextromethorphan, and is a norepinephrine and dopamine reuptake inhibitor, and a nicotinic acetylcholine receptor antagonist.